Seagen, Genmab Present Tisotumab Vedotin Combo Data In Cervical Cancer
Seagen Inc (NASDAQ:SGEN) and Genmab A/S (NASDAQ:GMAB) have interim data from two Phase 1b/2 innovaTV 205 trial cohorts. The trial is evaluating its…
Jefferies Downgrades Genmab to Hold
Jefferies analyst Peter Welford downgrades Genmab (NASDAQ:GMAB) from Buy to Hold.
Clinical Trial of Investigational Epcoritamab In Patients With Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma Published In The Lancet
Genmab A/S (NASDAQ:GMAB) and AbbVie (NYSE:ABBV) today announced The Lancet published the results of the dose escalation part of the phase 1/2 EPCORE™ NHL-1 first-in-human (FIH) dose escalation and cohort expansion
Morgan Stanley Downgrades Genmab to Underweight, Announces $37 Price Target
Morgan Stanley analyst Matthew Harrison downgrades Genmab (NASDAQ:GMAB) from Equal-Weight to Underweight and announces $37 price target.
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 2)
The Daily Biotech Pulse: Cara’s Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 23)